Seaport Global Advisors LLC Has $882,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Seaport Global Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 64.2% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 839 shares of the biopharmaceutical company’s stock after purchasing an additional 328 shares during the period. Regeneron Pharmaceuticals comprises approximately 3.2% of Seaport Global Advisors LLC’s holdings, making the stock its 8th largest holding. Seaport Global Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $882,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. West Paces Advisors Inc. grew its stake in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares in the last quarter. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $26,000. Sachetta LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $28,000. Finally, Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $33,000. 83.31% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the sale, the executive vice president now owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,033 shares of company stock valued at $9,399,345. 7.48% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on REGN. Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Truist Financial reaffirmed a “buy” rating and set a $1,200.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Barclays increased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,118.62.

Regeneron Pharmaceuticals Stock Up 0.3 %

Shares of REGN opened at $1,042.69 on Monday. The firm has a 50 day simple moving average of $1,128.91 and a two-hundred day simple moving average of $1,035.51. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The company has a market cap of $114.89 billion, a P/E ratio of 30.80, a P/E/G ratio of 3.57 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter in the previous year, the firm earned $8.79 EPS. Regeneron Pharmaceuticals’s revenue was up 12.3% on a year-over-year basis. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.